Pharmafile Logo
Pharmafocus logo
Advanced Search

lilly

Showing 15 posts of 210 posts found.

Eli Lilly front sign

Lilly’s COVID-19 drug has EUA revoked in favour of combination therapy

April 19, 2021
Sales and Marketing COVID-19, Eli Lilly, FDA, covid-19 treatment, lilly, pharma, pharma news

The FDA have revoked Emergency Use Authorization (EUA) of Eli Lilly’s bamlanivimab drug for the treatment of COVID-19, per the …

News
Eli Lilly building

Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial

March 17, 2021
Research and Development Eli Lilly, Phase III trial, lilly, mirikizumab, ulcerative colitis

Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and all key secondary endpoints in …

News
Eli Lilly front sign

University of Glasgow and Lilly sign £4.6m immunological disease partnership

February 15, 2021
Sales and Marketing Eli Lilly, University of Glasgow, arthritis, fibrosis, lilly, uofg

The University of Glasgow and Eli Lilly and Company have entered into a research collaboration, across four diseases, worth £4.6 …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

July 31, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Roche, UK government, Vaccine, lilly, pharma, top 10

Another week dominated by COVID-19. Among our most popular stories this week, Celltrion’s infliximab biosimilar Remsima has scored approval for …

News

Lilly promises $850 million investment in message to White House

March 27, 2017
Manufacturing and Production, Sales and Marketing Eli Lilly, President trump, lilly

Eli Lilly’s latest press release indicated that it would be spending $850 million in developing its worldwide US operations, particularly …

News

Lilly posts impressive psoriasis results in comparison study

March 6, 2017
Research and Development, Sales and Marketing J&J, JJ, Stelara, Taltz, lilly

Eli Lilly has revealed strong results in a study comparing its psoriasis treatment, Taltz (ixekizumab), to Johnson & Johnson’s Stelara. …

News
lillycorporatehq

Lilly three strikes in three years not out in Teva patent challenge

January 13, 2017
Medical Communications, Sales and Marketing Eli Lilly, Teva, generics, lilly, patent

Eli Lilly has successfully won a major patent case against Teva Pharmaceuticals, with the case being decided at the US …

News

MSD and Lilly announce immuno-oncology collaboration

January 11, 2017
Medical Communications, Research and Development Eli Lilly, Lartruvo, MSD, keytruda, lilly

MSD, known as Merck in North America, and Eli Lilly have announced the expansion of their existing immuno-oncology collaboration. The …

News
shutterstock_38078521

AZ and Lilly come together to battle Alzheimer’s

December 9, 2016
Research and Development, Sales and Marketing AZ, lilly

Pharma titans Eli Lilly and AstraZeneca have announced they are to join forces to co-develop a potential Alzheimer’s treatment, currently …

News
astrazeneca_logo_building

FDA fast tracks Alzheimer’s drug from Lilly, AstraZeneca

August 22, 2016
Manufacturing and Production, Research and Development Alzheimer's disease, AstraZeneca, BACE, lilly, phase III

AstraZeneca and Eli Lilly have announced that the US Food and Drug Administration (FDA) has granted AZD3293 its fast track …

News
lilly_research_labs_sign

Lilly showcases positive late-stage data in diabetes treatments

June 13, 2016
Research and Development, Sales and Marketing diabetes, lilly

Eli Lilly (NYSE: LLY) has presented data on their diabetes drugs in late-stage trials at the 76th American Diabetes Association …

News

Trial data shows promise for Lilly/MSD combo regimen in lung cancer

June 6, 2016
Research and Development, Sales and Marketing MSD, Merck, collaboration, immuno-oncology, lilly, lung cancer, non-small cell, parternship

Eli Lilly (NYSE: LLY) has presented data at the American Society of Clinical Oncology (ASCO) annual congress showcasing its collaborations …

News

FDA approves Lilly/Boehringer Ingelheim type-2 diabetes drug

June 1, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, diabetes, jentadueto, jentadueto xr, lilly, partnership, type 2, type-2

The US Food and Drug Administration (FDA) has approved Jentadueto XR (linagliptin and metformin hydrochloride extended release) tablets for the …

News
lilly_entrance_web

Eli Lilly showcases emerging pipeline to investors

May 25, 2016
Research and Development Eli Lilly, investors, lilly, pipeline, research and development

Eli Lilly and Co (NYSE: LLY) has showcased its emerging pipeline to potential investors, highlighting its potential to launch 20 …

News
lilly_entrance_web

FDA issues warning about rare, but serious, side effect in Lilly antipsychotic drug

May 12, 2016
Medical Communications, Sales and Marketing Eli Lilly, FDA, anti-psychotic, boxed warning, lilly, olanzapine, skin condition

The US Food and Drug Administration (FDA) has issued a new warning to all drug labels for Eli Lilly’s antipsychotic …

News

Latest content

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024

Intra-Cellular Therapies shares phase 3 results for major depressive disorder therapy

April 17, 2024

Novartis shares new data about Fabhalta for IgAN treatment

April 16, 2024